Cancer Immunotherapy Biotech Argos Therapeutics, Inc. Files For A $60 Million IPO
Published: Dec 31, 2013
Argos Therapeutics, which is developing immunotherapies for the treatment of cancer and infectious diseases, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The Durham, NC-based company, which was founded in 1997 and booked $5 million in collaboration and grant revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol ARGS.
Help employers find you! Check out all the jobs and post your resume.